Today: 1 May 2026
AMD stock slips after-hours as CES AI chip pitch meets “show me” market mood
8 January 2026
2 mins read

AMD stock slips after-hours as CES AI chip pitch meets “show me” market mood

NEW YORK, Jan 8, 2026, 16:41 EST — After-hours

  • AMD fell about 2.5% after hours, extending a pullback in AI-linked chip stocks.
  • Investors weighed AMD’s CES chip roadmap against tight competition and fresh China-related headlines across the sector.
  • The next key catalyst is AMD’s Feb. 3 earnings report, with Friday’s U.S. jobs data a nearer-term market test.

Advanced Micro Devices (AMD.O) shares were down 2.5% at $204.68 in after-hours trading on Thursday, after swinging between $203.35 and $211.51 in the session.

The late dip matters because AMD is heading into its next earnings report with investors still trying to price how quickly its new AI (artificial intelligence) hardware turns into shipped systems and recurring orders. The stock’s slide also puts a round-number $200 level back on screens for short-term traders.

Wall Street’s tone did not help. U.S. stocks ended mixed, with technology shares sliding as investors picked through pricey AI winners and losers. “It’s become a ‘show me’ sector,” Art Hogan, chief market strategist at B. Riley Wealth, said, referring to capex, or capital spending, and the push for clearer payoffs. Reuters

AMD spent part of this week trying to give that payoff story more shape. At CES in Las Vegas on Monday, CEO Lisa Su showcased the MI455 AI processors used in server racks the company is selling to customers including OpenAI, and introduced the MI440X chip aimed at on-premise (in-house) enterprise deployments. Su also previewed the MI500 series for 2027 and rolled out new Ryzen AI PC processors, as Nvidia and Intel pushed their own CES launches.

The sector also had fresh China headlines to digest. Reuters reported Nvidia is asking Chinese customers to pay in full upfront for H200 AI chips as it hedges against uncertainty over Beijing’s approvals; Nvidia CEO Jensen Huang said demand was “quite high” and the company has “fired up our supply chain” to ramp output. Investors often read those cross-currents — approvals, payment terms, and export rules — as a proxy for how messy the next leg of AI hardware demand could get. Reuters

For AMD specifically, the next hard checkpoint is results. The company said it will report fiscal fourth-quarter and full-year 2025 results on Tuesday, Feb. 3, after the market close, followed by a conference call at 5:00 p.m. EST. Traders will be listening for updates on data-center momentum, AI accelerator shipments, and whether customer rollouts are speeding up or getting pushed out.

But the setup cuts both ways. If customers slow orders, delay deployments, or lean harder into a rival’s software stack, the market can punish expectations quickly — especially in a tape that is starting to demand cleaner evidence of returns from AI spending.

Next up is Friday’s U.S. nonfarm payrolls report, a macro event traders have flagged as a key test for rate-cut timing and risk appetite, before attention swings back to AMD’s Feb. 3 earnings and any follow-through from CES bookings and China policy headlines.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:13 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Meta stock dips as China opens Manus AI deal review — what investors watch next
Previous Story

Meta stock dips as China opens Manus AI deal review — what investors watch next

XRP price slips as spot ETF outflows break streak; U.S. jobs report in focus
Next Story

XRP price slips as spot ETF outflows break streak; U.S. jobs report in focus

Go toTop